Ads
related to: metastatic renal cell carcinoma- How This Treatment Works
Learn More About How This
FDA-Approved Treatment Works.
- FAQs
Find FAQs For This Treatment
Option On The Official Patient Site
- Dosing Information
Get Dosing And Treatment
Schedule Information.
- Patient Resources
Find Patient Resources
On The Official Site.
- How This Treatment Works
Search results
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 7 days agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 3 days agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients ...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 8 hours agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 4 days agoInvestors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for...
Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
Forbes· 5 days agoThis article is part of an ongoing series on novel cancer advances, including immunotherapies such...
Bavencio Side Effects: What They Are and How to Manage Them
Healthline· 3 days agoBavencio (avelumab) is a prescription drug used to treat certain types of kidney, bladder, and skin cancer. Bavencio can cause side effects that range from mild to serious. Examples include ...
Nexavar Dosage: Form, Strength, How to Take, and More
Healthline· 4 days agoNexavar (sorafenib) is a prescription drug used to treat liver, kidney, and thyroid cancers. Nexavar belongs to a group of drugs called kinase inhibitors and contains the active ingredient sorafenib ...
Q2 2024 EPS Estimates for Janux Therapeutics, Inc. Cut by William Blair (NASDAQ:JANX)
ETF DAILY NEWS· 15 hours agoJanux Therapeutics, Inc. (NASDAQ:JANX – Free Report) – Stock analysts at William Blair reduced their Q2 2024 earnings estimates for shares of Janux Therapeutics in a research note issued on ...
HC Wainwright Reaffirms Buy Rating for Exelixis (NASDAQ:EXEL)
ETF DAILY NEWS· 5 days agoHC Wainwright reaffirmed their buy rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a research report sent to investors on Friday, Benzinga reports. Several other equities analysts ...